These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 19950378)
1. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Watkins JM; Zauls AJ; Wahlquist AH; Shirai K; Garrett-Mayer E; Gillespie MB; Day TA; Sharma AK Laryngoscope; 2010 Feb; 120(2):236-42. PubMed ID: 19950378 [TBL] [Abstract][Full Text] [Related]
2. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515 [TBL] [Abstract][Full Text] [Related]
3. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764 [TBL] [Abstract][Full Text] [Related]
4. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118 [TBL] [Abstract][Full Text] [Related]
6. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475 [TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma. Barone C; Grillo R; Dongiovanni D; Birocco N; Rampino M; Redda MG; Garibaldi E; Munoz F; Pecorari G; Cavalot A; Garzinodemo P; Buffoni L; Ciuffreda L; Ricardi U; Cortesina G; Giordano C; Fasolis M; Berrone S; Bertetto O; Schena M Anticancer Res; 2008; 28(2B):1285-91. PubMed ID: 18505067 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722 [TBL] [Abstract][Full Text] [Related]
12. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114 [TBL] [Abstract][Full Text] [Related]
13. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028 [TBL] [Abstract][Full Text] [Related]
14. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320 [TBL] [Abstract][Full Text] [Related]
15. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial. Kumar S; Pandey M; Lal P; Rastogi N; Maria Das KJ; Dimri K Radiother Oncol; 2005 May; 75(2):186-92. PubMed ID: 16086908 [TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541 [TBL] [Abstract][Full Text] [Related]
17. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776 [TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971 [TBL] [Abstract][Full Text] [Related]
19. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]